The pharmaceutical landscape has been fundamentally reshaped by the meteoric rise of GLP-1 receptor agonists. What began as a specialized treatment for type 2 diabetes has, in less than a decade, evolved into a sprawling therapeutic category that touches upon cardiology, hepatology, neurology, and oncology. This "GLP-1 wave" is not merely a story of drug approvals; it is a profound shift in clinical research requirements, creating an urgent, unmet demand for a new generation of biospecimens and deeply annotated patient datasets.
As the therapeutic scope of these drugs expands, the research community is realizing that the biobanks of yesterday—optimized for simple metabolic endpoints—are no longer sufficient to solve the complex biological puzzles presented by the drug class’s latest applications.
A Rapid Evolution: The GLP-1 Chronology
The pace at which this drug class has moved from niche endocrinology to systemic medicine is unprecedented in modern pharmacology.
- 2017: Semaglutide (Ozempic) receives FDA approval for type 2 diabetes, establishing the foundation for the class.
- 2021: The approval of semaglutide (Wegovy) for chronic weight management signals the dawn of the obesity-treatment era.
- 2022: Tirzepatide (Mounjaro), a dual GIP/GLP-1 agonist, enters the market, offering increased efficacy for type 2 diabetes.
- 2023: Tirzepatide (Zepbound) gains approval for obesity, intensifying competition in the space.
- March 2024: Wegovy secures a landmark clearance to reduce cardiovascular risk, marking the first time a weight-loss drug is recognized for its life-saving cardiac benefits.
- December 2024: Zepbound achieves another "first," becoming the inaugural FDA-approved treatment for obstructive sleep apnea.
- January 2025: Ozempic is approved to slow the progression of chronic kidney disease (CKD) in diabetic patients.
- August 2025: Wegovy breaks new ground as the first GLP-1 therapy indicated for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with moderate-to-advanced fibrosis.
- December 2025: The approval of the oral Wegovy pill democratizes access to GLP-1 therapy for weight loss.
- April 2026: Orforglipron (Foundayo), the first oral small-molecule GLP-1, is cleared for obesity, benefiting from the fastest new-drug review process since 2002.
The Economic and Clinical Ripple Effect
As of July 1, 2026, the inclusion of GLP-1 drugs for weight loss under Medicare coverage represents a seismic shift in public health. With monthly costs stabilized at roughly $50 for covered patients, the accessibility of these drugs has surged. Prior to this, the high list prices—often exceeding $1,000 per month—created a significant barrier to entry, leaving roughly half of the one-in-eight American adults currently taking these medications struggling with affordability.
However, the rapid expansion of these drugs into chronic disease areas has created a secondary, less visible challenge: the "specimen gap." Researchers are now pivoting toward the study of MASH, neurodegeneration, and obesity-linked cancers, but the biological samples currently residing in biobanks were largely collected for metabolic and weight-loss studies. These older collections often lack the specific comorbidities, longitudinal medical history, or tissue types required for the next generation of discovery.
Expert Insight: The Shift from Tissue to Biofluids
Cathie Miller, Ph.D., director of product management operations at BioIVT, emphasizes that the evolution of GLP-1 research has necessitated a complete reassessment of biospecimen procurement.
"If you think about what GLP-1s were first developed for, a lot of it was around weight loss," Miller explains. "As the science has evolved, and we’ve gotten a better understanding of how these drugs can potentially work for other diseases, those original samples the biobanks collected are no longer as relevant. The weight-loss-era banks are not going to have the oncology samples, the tumors, or the neurological conditions."
This realization has driven a strategic pivot in the biospecimen industry. Where surgical resection of tissue once served as the gold standard for research, the industry is increasingly favoring biofluids. "Ten years ago, it was predominantly tissue," says Miller. "Now, we’re seeing a drive toward biofluids—plasma, serum, whole blood, but also urine, feces, and saliva. We’ve seen our own book of business shift from a 60/40 split in favor of tissue to a 60/40 split in favor of biofluids."
This transition is bolstered by advances in exosome research and liquid biopsy analysis, which allow scientists to glean high-fidelity biological information without the need for invasive surgical procedures.
New Indications, New Specimen Requirements
The approval of Wegovy for MASH in August 2025 serves as a prime example of how a new indication dictates the requirements for biospecimens. Before this approval, standard hepatocytes were often sufficient for testing. Today, sponsors require liver models that accurately reflect the disease’s pathology, including "liver-fatty" scores and chronic fibrotic markers.
Brian Ogilvie, Ph.D., vice president of scientific consulting at BioIVT, notes the pressure this places on ADME (Absorption, Distribution, Metabolism, and Excretion) testing. "People are asking for scores for liver fattiness," Ogilvie notes. "It’s difficult to get a true diagnosis, but they are looking for samples that exhibit those characteristics. We’ve had to adapt our HEPATOPAC services to facilitate the kind of long-term, chronic testing that these new MASH-focused agents demand."
The Neurodegeneration Hurdle
Perhaps the most challenging frontier is the central nervous system. Despite high-profile trial disappointments—such as the EVOKE and EVOKE+ trials for Alzheimer’s, and the Exenatide-PD3 study for Parkinson’s—the scientific community remains committed to the hypothesis that GLP-1s hold potential in neurodegeneration.
Because brain tissue is largely inaccessible in living patients, researchers have pivoted to cerebrospinal fluid (CSF). The current challenge is that simply having CSF is not enough; researchers require well-characterized, clinically annotated samples that allow them to correlate biomarker fluctuations with disease progression, even when primary clinical outcomes remain elusive.
Implications: The Power of Clinical Annotation
The value of a biospecimen in 2026 is no longer defined by the sample alone, but by the "data wrapper"—the clinical context that accompanies it.
"If it’s a biobank like BioIVT’s, we collect as much medical history as the donor will provide," Miller says. "We know whether, after being on a GLP-1, the donor did or did not develop cancer. That is where we are making a concerted effort to add value."
As the global biospecimen procurement market marches toward an projected $11 billion valuation by 2033, the barrier to progress will not be a lack of samples, but a lack of relevant samples. With four in five researchers reporting that they have had to narrow their study scopes due to difficulties in obtaining high-quality, well-annotated specimens, the biobanking industry finds itself at a critical juncture.
The future of drug discovery in the post-GLP-1 era depends on the ability to bridge the gap between historical data and modern medical necessity. The industry is no longer just selling tubes of blood or tissue; it is selling the precision required to move from treating symptoms to potentially curing the most complex, systemic diseases of our time.
The GLP-1 wave has changed everything—from how we define metabolic health to how we view the sanctity and utility of the human biological record. As researchers continue to explore the limits of this drug class, the biobanks that thrive will be those that can successfully anticipate the next therapeutic frontier before it arrives.
About the Author
